IP Library Granted Patent US 8,883,992
Granted Patent B2
US 8,883,992 · App. 13/661,138 · Granted Nov 11, 2014

Humanized anti-CD19 antibodies

Inventors: Melissa Damschroder (Germantown, MD); Peter Kiener (Potomac, MD); Herren Wu (Boyds, MD); William Dall'Acqua (Gaithersburg, MD); Ronald Herbst (Potomac, MD); Anthony Coyle (Boston, MA)
Assignee: Medimmune, LLC
C07K16/2896C07K2317/565C07K2317/41C07K2317/52A61K2039/505C07K2317/567C07K2317/56C07K2317/732C07K16/2803C07K2317/24C07K2317/77C07K2317/92C07K2317/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,992
App. No.
13/661,138
Granted
Nov 11, 2014
Kind
B2
Abstract

Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.

Claims (9)

1. An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence comprising SEQ ID NO: 106.

2. An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence comprising SEQ ID NO: 111.

3. An expression vector comprising the nucleic acid of claim 1 .

4. An expression vector comprising the nucleic acid of claim 2 .

5. An expression vector comprising an isolated nucleic acid encoding an antibody comprising the amino acid sequence of SEQ ID NO: 106 and 111, wherein the antibody binds a CD19 antigen.

6. A host cell transfected with the vector of claim 1 .

7. A host cell transfected with the vector of claim 2 .

8. A host cell transfected with the vector of claim 5 .

9. A method of producing an antibody comprising culturing host cells according to claim 8 under conditions for production of the antibody.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA HORIZON ORPHAN LLC); HORIZON THERAPEUTICS USA, INC.; VIELA BIO, INC.
Reel/Frame 065154/0064 →
SECURITY AGREEMENT Recorded Mar 15, 2021
From: HORIZON ORPHAN LLC; HORIZON THERAPEUTICS USA, INC.; VIELA BIO, INC.
To: CITIBANK, N.A.
Reel/Frame 055659/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2018
From: MEDIMMUNE, LLC
To: VIELA BIO, INC.
Reel/Frame 045648/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2013
From: DAMSCHRODER, MELISSA; KIENER, PETER; WU, HERREN; DALL'ACQUA, WILLIAM; HERBST, RONALD; COYLE, ANTHONY
To: MEDIMMUNE, INC.
Reel/Frame 031017/0880 →
CHANGE OF NAME Recorded Aug 15, 2013
From: MEDIMMUNE, INC.
To: MEDIMMUNE, LLC
Reel/Frame 031030/0320 →
Continuity (7)
Continuation 11852106 · Sep 7, 2007
Provisional Application 60939429 · May 22, 2007
Provisional Application 60915309 · May 1, 2007
Provisional Application 60911397 · Apr 12, 2007
Provisional Application 60866917 · Nov 22, 2006
Provisional Application 60842935 · Sep 8, 2006
Related Publication 20130115657A1 · May 9, 2013